There is an upcoming phase I/II trial studying how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis, however, it’s important for you to seek the opinion of an MDS expert to determine if this trial, or any other trial, may be the right fit for you. It’s highly recommended that you go to an MDS Center of Excellence. You should be very carefully assessed before undergoing any treatment. Benefits versus risk analysis should be done with any treatment. Following is a link to the Centers of Excellence worldwide https://www.mds-foundation.org/mds-centeres-of-excellence/.